Sana Biotechnology is actively progressing its hypoimmune technology across three clinical trials, targeting five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology. These trials are designed to evaluate the safety and efficacy of Sana's novel cell therapies, which incorporate the company's proprietary hypoimmune platform to prevent immune rejection.
Ongoing Clinical Trials
Sana Biotechnology is currently enrolling patients in three key clinical trials:
- Investigator-Sponsored Trial: This trial utilizes hypoimmune-modified primary islet cells for the treatment of type 1 diabetes.
- GLEAM Trial: The GLEAM trial is evaluating SC291 in patients with B-cell mediated autoimmune diseases.
- VIVID Trial: The VIVID trial is assessing SC262 in patients with relapsed or refractory B-cell malignancies.
Sana anticipates data from these studies in 2024 and/or 2025. "This past quarter was an important one for our clinical programs," said Steve Harr, Sana’s President and Chief Executive Officer. "Each of our lead programs is now enrolling patients in the clinic, and we are generating meaningful learnings to inform continued development of hypoimmune-modified cell therapies."
Hypoimmune Platform
Sana Biotechnology's hypoimmune platform is designed to enable the creation of cell therapies that can evade immune detection and rejection. This technology involves modifying cells to reduce the expression of major histocompatibility complex (MHC) class I and II molecules, which are key targets for immune recognition. By minimizing immune responses, Sana aims to develop cell therapies that can be administered without the need for immunosuppression.
Third Quarter 2024 Financial Results
Sana Biotechnology reported its third quarter 2024 financial results, highlighting its ongoing investments in research and development. The company’s financial position supports its continued advancement of the hypoimmune platform and clinical programs.
Preclinical Updates
Sana Biotechnology continues to advance its preclinical pipeline, with a focus on developing novel cell therapies for a range of diseases. These efforts include optimizing cell engineering strategies and evaluating the efficacy of hypoimmune-modified cells in preclinical models.
About Sana Biotechnology
Sana Biotechnology is focused on creating and delivering engineered cells as medicine for patients. Sana shares a vision of repairing and controlling disease by delivering the right cells, with the right attributes, to the right place in the body. Sana employs more than 400 people, with locations in Seattle, Cambridge, South San Francisco, and Rochester.
